NTx Bio
NTx Bio (Nature’s Toolbox, Inc.) is revolutionizing biomanufacturing by enabling on-demand, decentralized, and scalable production of high-quality RNA and proteins. Our mission is to democratize access to medicines by overcoming the bottlenecks of traditional, centralized manufacturing. Through proprietary, synthetic biology platforms like NTxscribe® (mRNA production) and NTxpress® (cell free protein production), NTx empowers researchers and companies to accelerate the development and delivery of personalized and mass-scale therapeutics, making next-generation medicine more accessible, sustainable, and efficient, while eliminating supply chain concerns by using 100% domestic inputs and production capabilities.
Industries
Nr. of Employees
small (1-50)
NTx Bio
7701 Innovation Way NE, Rio Rancho, NM 87144
Products
Benchtop continuous-flow RNA IVT and purification system
Compact automated system implementing continuous-flow IVT in hollow-fiber reactors with co-transcriptional capping and inline purification. Designed to produce high-integrity mRNA/saRNA on a benchtop footprint with linear scalability from mg to gram scale and rapid cycle times (reported ~10–65+ mg output in ~3 hours). Single-use closed-system options and integration points for in-line analytics.
Fully recombinant cell-free protein synthesis platform
Recombinant, thermostable cell-free transcription/translation platform engineered to produce high-yield, high-purity proteins without crude cell extracts, including an ATP regeneration system and compatibility with linear and circular DNA templates.
Benchtop continuous-flow RNA IVT and purification system
Compact automated system implementing continuous-flow IVT in hollow-fiber reactors with co-transcriptional capping and inline purification. Designed to produce high-integrity mRNA/saRNA on a benchtop footprint with linear scalability from mg to gram scale and rapid cycle times (reported ~10–65+ mg output in ~3 hours). Single-use closed-system options and integration points for in-line analytics.
Fully recombinant cell-free protein synthesis platform
Recombinant, thermostable cell-free transcription/translation platform engineered to produce high-yield, high-purity proteins without crude cell extracts, including an ATP regeneration system and compatibility with linear and circular DNA templates.
Expertise Areas
- Cell-free biomanufacturing
- mRNA and self-amplifying RNA production
- Cell-free protein expression
- Continuous-flow bioprocessing and hollow-fiber reactors
Key Technologies
- Hollow-fiber continuous-flow bioreactors
- Co-transcriptional 5' capping
- Tangential flow filtration (TFF) purification
- Fully recombinant cell-free transcription/translation
Key People
President & Chief Executive Officer
Chief Scientific Officer & Senior Vice President R&D
Chief Financial Officer
Chief Operating Officer
Senior Vice President, Business Development
Vice President, Corporate Development
President & Chief Executive Officer
Chief Scientific Officer & Senior Vice President R&D
Chief Financial Officer
Chief Operating Officer
Senior Vice President, Business Development
Vice President, Corporate Development
News & Updates
NTx was recognized as a Top 10 Drug Discovery Company by Pharma Tech Outlook.
NTx raised $47.5 million in Series B funding to accelerate its biomanufacturing platforms.
NTx received a BARDA DRIVe contract to demonstrate its NTxscribe® platform for rapid RNA vaccine manufacturing in collaboration with Houston Methodist Hospital.
NTx is working on materials to improve global access to vaccines, supporting rapid and scalable vaccine manufacturing.
Rio Rancho Mayor discusses the positive economic impact of NTx’s presence in the region.
Site Selection Magazine features NTx as a transformative company in the biomanufacturing sector.
NTx was recognized as a Top 10 Drug Discovery Company by Pharma Tech Outlook.
NTx raised $47.5 million in Series B funding to accelerate its biomanufacturing platforms.
NTx received a BARDA DRIVe contract to demonstrate its NTxscribe® platform for rapid RNA vaccine manufacturing in collaboration with Houston Methodist Hospital.
NTx is working on materials to improve global access to vaccines, supporting rapid and scalable vaccine manufacturing.
Rio Rancho Mayor discusses the positive economic impact of NTx’s presence in the region.
Site Selection Magazine features NTx as a transformative company in the biomanufacturing sector.